Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Aridis Pharmaceuticals Stories

2013-05-17 08:22:58

SAN JOSE, Calif., May 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased to announce that an agreement has been reached with Switzerland-based Kenta Biotech to acquire Kenta's entire portfolio of anti-infective human monoclonal antibody (mAb) products, and technologies. This asset portfolio purchase includes six anti-infective human mAb products for treatment of infections by common pathogens including drug resistant bacterial strains of Staphylococcus aureus, Pseudomonas aeruginosa,...